ATN-161   Click here for help

GtoPdb Ligand ID: 14587

Synonyms: ATN161 | N-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl-L-asparaginamide
Compound class: Peptide
Comment: ATN-161 is a penta-peptide integrin α5β1 antagonist [5]. It interferes with the interaction between the integrin on endothelial cells and fibronection in the extracellular matrix (ECM) [3]. ATN-161 was primarily proposed as an anti-tumour agent with potential to disrupt neoangiogenesis [1,5,7]. It has subsequently been explored for antimicrobial/anti-infection potential [2,4,6,9].
Click here for help
2D Structure
Click here for help
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N
Isomeric SMILES CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N
InChI InChI=1S/C23H35N9O8S/c1-11(34)32-4-2-3-17(32)23(40)29-14(5-12-7-26-10-27-12)20(37)30-15(8-33)21(38)31-16(9-41)22(39)28-13(19(25)36)6-18(24)35/h7,10,13-17,33,41H,2-6,8-9H2,1H3,(H2,24,35)(H2,25,36)(H,26,27)(H,28,39)(H,29,40)(H,30,37)(H,31,38)/t13-,14-,15-,16-,17-/m0/s1
InChI Key MMHDBUJXLOFTLC-WOYTXXSLSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes G, Lewis N, Weiner L, Lam GN, Brown SC et al.. (2006)
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.
Br J Cancer, 94 (11): 1621-6. [PMID:16705310]
2. Gracie NP, Aggarwal A, Luo R, Spicer M, Idrees S, Ashley CL, Alca S, Ison T, Steain MC, Patel K et al.. (2025)
An RGD motif on SARS-CoV-2 Spike induces TGF-β signaling and downregulates interferon.
J Virol, 99 (9): e0043525. [PMID:40905682]
3. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Doñate F, Shaw DE, Mazar AP, Rabbani SA. (2006)
A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.
Mol Cancer Ther, 5 (9): 2271-80. [PMID:16985061]
4. Liu X, Yuan Z, Wan Z, Yuan X, Wang Y, Gao Y, Zhang L, Song R, Sang J, Wang Y et al.. (2026)
P. gingivalis-host interactions direct antibiotic adjuvants for periodontitis antimicrobial therapy.
Int J Oral Sci, 18 (1). [PMID:42425934]
5. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S, Upadhyaya A. (2000)
Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma.
Cancer Res, 60 (2): 309-20. [PMID:10667582]
6. Silva RS, Souza LMP, Costa RKM, Souza FR, Pimentel AS. (2023)
Absolute binding free energies of the antiviral peptide ATN-161 with protein targets of SARS-CoV-2.
J Biomol Struct Dyn, 41 (20): 10546-10557. [PMID:36476274]
7. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, McCarty MF, Bucana CD, Mazar AP, Ellis LM. (2003)
Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice.
Int J Cancer, 104 (4): 496-503. [PMID:12584749]
8. White ES, Livant DL, Markwart S, Arenberg DA. (2001)
Monocyte-fibronectin interactions, via alpha(5)beta(1) integrin, induce expression of CXC chemokine-dependent angiogenic activity.
J Immunol, 167 (9): 5362-6. [PMID:11673553]
9. Zhang H, Wang Z, Nguyen HTT, Watson AJ, Lao Q, Li A, Zhu J. (2023)
Integrin α5β1 contributes to cell fusion and inflammation mediated by SARS-CoV-2 spike via RGD-independent interaction.
Proc Natl Acad Sci U S A, 120 (50): e2311913120. [PMID:38060559]